Vera Therapeutics, Inc.
VERA
$28.82
-$0.48-1.64%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 64.09% | 18.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.78% | 33.36% | |||
| Operating Income | 1.78% | -33.36% | |||
| Income Before Tax | 6.88% | -38.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.88% | -38.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.88% | -38.34% | |||
| EBIT | 1.78% | -33.36% | |||
| EBITDA | 1.84% | -38.86% | |||
| EPS Basic | 15.76% | -37.91% | |||
| Normalized Basic EPS | 15.77% | -37.93% | |||
| EPS Diluted | 15.76% | -37.91% | |||
| Normalized Diluted EPS | 15.77% | -37.93% | |||
| Average Basic Shares Outstanding | 10.56% | 0.31% | |||
| Average Diluted Shares Outstanding | 10.56% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
